CA2896979C - Methods for purification of arylsulfatase a - Google Patents

Methods for purification of arylsulfatase a Download PDF

Info

Publication number
CA2896979C
CA2896979C CA2896979A CA2896979A CA2896979C CA 2896979 C CA2896979 C CA 2896979C CA 2896979 A CA2896979 A CA 2896979A CA 2896979 A CA2896979 A CA 2896979A CA 2896979 C CA2896979 C CA 2896979C
Authority
CA
Canada
Prior art keywords
chromatography
protein
asa
column
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2896979A
Other languages
English (en)
French (fr)
Other versions
CA2896979A1 (en
Inventor
Dave Nichols
Igor Quinones-Garcia
Bee Lin CHEANG
Mei Huei JANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CA2896979A1 publication Critical patent/CA2896979A1/en
Application granted granted Critical
Publication of CA2896979C publication Critical patent/CA2896979C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2896979A 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a Active CA2896979C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Publications (2)

Publication Number Publication Date
CA2896979A1 CA2896979A1 (en) 2014-07-17
CA2896979C true CA2896979C (en) 2023-05-02

Family

ID=50002885

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896979A Active CA2896979C (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN112126634A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729566B1 (en) * 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP2943568B1 (en) 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
US20160176921A1 (en) * 2014-12-22 2016-06-23 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
EP3337819B1 (en) * 2015-08-20 2024-02-21 F. Hoffmann-La Roche AG Method of purifying for producing recombinant polypeptides using fkpa
WO2017160636A1 (en) * 2016-03-16 2017-09-21 Shire Human Genetic Therapies, Inc. Methods of purifying collagen 7
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
AU2018393045C1 (en) * 2017-12-19 2025-10-09 Takeda Pharmaceutical Company Limited Purified arylsulfatase A and compositons thereof
SG11202006506TA (en) * 2018-02-02 2020-08-28 Enzyvant Therapeutics Gmbh Methods for treating farber disease
MA52204A (fr) * 2018-04-12 2021-02-17 Amgen Inc Procédés de préparation de compositions protéiques stables
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
AU2020401034B2 (en) * 2019-12-12 2024-08-29 Eli Lilly And Company Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
JP4685238B2 (ja) 1998-06-09 2011-05-18 ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ／エス ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2002232803A1 (en) 2000-11-15 2002-05-27 Genzyme Corporation Expression system for recombinant proteins
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
ES2496493T3 (es) 2002-01-11 2014-09-19 Bioasis Technologies Inc. Uso de p97 como sistema de administración de enzimas para la administración de enzimas lisosómicas terapéuticas
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
MX2008012748A (es) 2006-04-04 2009-01-07 Shire Pharmaceuticals Ireland Un proceso para la concentracion de un polipeptido.
CA2739352C (en) * 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
AU2011270670B2 (en) * 2010-06-25 2017-01-12 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
EP2588130B1 (en) 2010-06-25 2016-08-17 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
EP2943568B1 (en) 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a

Also Published As

Publication number Publication date
EA201590826A1 (ru) 2015-11-30
US11407984B2 (en) 2022-08-09
AU2014205441A1 (en) 2015-06-25
JP7407161B2 (ja) 2023-12-28
EA030551B1 (ru) 2018-08-31
US20240392268A1 (en) 2024-11-28
AU2014205441B2 (en) 2019-12-12
CN112126634A (zh) 2020-12-25
BR112015015948A2 (enExample) 2017-08-15
CN120665836A (zh) 2025-09-19
AU2022221475B2 (en) 2025-05-22
JP2020015750A (ja) 2020-01-30
US20230235303A1 (en) 2023-07-27
US11884945B2 (en) 2024-01-30
AU2020201079B2 (en) 2022-05-26
CA2896979A1 (en) 2014-07-17
CN119979504A (zh) 2025-05-13
AU2020201079A1 (en) 2020-03-05
US12319940B2 (en) 2025-06-03
MX2020003798A (es) 2020-08-03
MX2015008875A (es) 2015-10-22
HK1216429A1 (en) 2016-11-11
WO2014110246A1 (en) 2014-07-17
US20150353904A1 (en) 2015-12-10
EP2943568B1 (en) 2019-11-20
HK1214622A1 (zh) 2016-07-29
JP6427502B2 (ja) 2018-11-21
MX372711B (es) 2020-04-21
ES2768261T3 (es) 2020-06-22
AU2022221475A1 (en) 2022-09-22
EP2943568A1 (en) 2015-11-18
CN104903442A (zh) 2015-09-09
JP2022023225A (ja) 2022-02-07
BR112015015948B1 (pt) 2022-05-17
JP2016504040A (ja) 2016-02-12
JP2018171067A (ja) 2018-11-08
JP2024001160A (ja) 2024-01-09
JP7663649B2 (ja) 2025-04-16

Similar Documents

Publication Publication Date Title
AU2022221475B2 (en) Methods for purification of arylsulfatase a
AU2018200230B2 (en) Purification of iduronate-2-sulfatase
HK1216429B (en) Methods for purification of arylsulfatase a
WO2024176112A1 (en) Large scale production of recombinant arylsulfatase a and compositions thereof
EP4545141A2 (en) Purified arylsulfatase a and compositions thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241224